MEDARTIS: Reaching for the stars, in post-COVID extremities | BUY | CHF80 VS. 60(-2%)
MEDARTIS - BUY | CHF80 VS. 60(-2%)Reaching for the stars, in post-COVID extremities
US strategy paying off
KeriMedical allows Medartis to touch new markets
More M&A on the agenda
Update estimates TP EUR 80 (from EUR 60), retain BUY
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.